China authorises emergency use of coronavirus vaccines, says health official

China’s health official on August 22 reportedly confirmed that country authorised emergency use of COVID-19 vaccines developed by some select domestic companies. While speaking to a Chinese media outlet, Zheng Zhongwei, who is he of coronavirus vaccine development task force, said that officials have drawn up a series of plan packs, including medical consent forms, side-effects monitoring plans, rescue plans, compensation plans, to make sure emergency use is well regulated and monitored. 

According to international media reports, emergency use authorisation is based on Chinese manment law. Under emergency authorisation, country will be able to use unapproved vaccine candidates among those who are at high risk of getting infected on a limited period. official informed that by first iculating special groups, including frontline workers, civil servants, move is to ensure that a city can keep rmal functions when a health crisis strikes. 

RE: China Approves Human Testing For A Potential Coronavirus Vaccine

Zheng reportedly said that China is planning to scale up iculating group to better prepare for a possible next wave in autumn and winter. It was ted that national ncy has alrey used several emergency use authorisation since coronavirus outbreak as a way to get many diagstic tests more quickly to market than rmal procedures. 

RE: Venezuela Offers Assistance In Producing COVID-19 Vaccine To Russia, China

Chinese firms conduct clinical trails 

Meanwhile, according to China’s National Medical Products ministration, at least eight potential coronavirus vaccines have entered different sts of clinical trials. Leing race, Chinese pharmaceutical firm, CanSi Biologics, has reportedly started a late-st trial of a COVID-19 vaccine candidate in Russia. potential coronavirus vaccine candidate has reportedly won a patent approval from Beijing. 

According to international media reports, 5-nCoV, which has alrey been approved for use by China’s military, is furr also set to begin late-st trials in Mexico and Saudi Arabia. Apart from CanSi Biologics, or Chinese firms, including Sivac Biotech Ltd and China National Pharmaceutical Group Co Ltd (Sipharm), are testing candidates overseas as China has become less conducive for Phase III trials due to its small number of new coronavirus cases. last-st trials is generally required for regulatory approval to distribute a vaccine for public use.

RE: China Reports 22 Imported COVID-19 Cases: Officials

RE: COVID-19: Beijing Allows People To Go Mask-free As Cases Drop In China